Activated Protein C Modulation of TGF-Beta Signaling for Scar Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pathological scars, such as hypertrophic and keloid scars, often result in unwanted side effects and limited efficacy, necessitating a more effective method to minimize their formation and appearance.
Innovation Solution
The use of activated protein C (APC) or its analogues, like APC-3K3A, to enhance TGF-β3 production while inhibiting TGF-β1 expression in skin cells, thereby preventing the formation and reducing the appearance of pathological scars.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pathological scars are used, then some therapeutic effect is achieved, but unwanted side effects occur and efficacy is limited
Solution Approach 1:
The patent changes the biochemical parameters of scar tissue by modulating the TGF-β1/TGF-β3 ratio. By administering TGF-β3 or inhibitors of TGF-β1, the treatment shifts the molecular profile of the scar tissue from a pathological state (high TGF-β1, low TGF-β3) toward a physiological state, thereby improving efficacy while avoiding the side effects associated with conventional treatments such as corticosteroids or surgical excision
Solution Approach 2:
The patent introduces TGF-β3 as an intermediary substance that mediates the transformation of pathological scar tissue. TGF-β3 acts as a counterbalancing factor to the excessive TGF-β1 activity, promoting normal wound healing pathways and reducing fibrosis without the harmful side effects of other interventions
2Manufacturing precision
If wound repair process is protracted beyond 3-4 weeks, then more complete tissue repair may occur, but likelihood of pathologic scar formation increases
Solution Approach 1:
The patent applies TGF-β3 or TGF-β1 inhibitors during the critical early wound healing phase (within the first 3-4 weeks) to prevent the dysregulation that leads to pathological scarring. By intervening early in the wound repair process, the treatment establishes a favorable biochemical environment that promotes physiological healing before abnormal fibrosis can develop
Solution Approach 2:
The patent utilizes the feedback mechanism of TGF-β signaling pathways to regulate wound healing. By introducing TGF-β3 or blocking TGF-β1, the treatment creates a negative feedback loop that prevents excessive collagen deposition and fibroblast proliferation, thereby maintaining wound repair quality while ensuring scar-free healing
Data Source
AI summary
The invention relates to the prevention and treatment of pathologic scars using APC or analogue thereof.